The energy supply strategy is a chronic adaptation in which the body maintains continuous glucose availability for immune cells through sustained cortisol-driven gluconeogenesis from protein breakdown, enabled by peripheral cortisol resistance that preserves immune cell sensitivity. This metabolic reconfiguration represents one of two essential survival strategies in chronic disease (alongside the growth and repair strategy) as described in the FILM meta-model, transforming the body into a glucose factory that prioritizes immune function at the expense of muscle mass, metabolic health, and long-term viability.
Imagine a city in permanent wartime where the army (immune system) demands constant fuel, but the normal food supply (dietary glucose, glycogen stores) ran out months ago. The city council (hypothalamus) keeps issuing emergency orders (cortisol) to tear down buildings (muscle tissue) and melt them into fuel (gluconeogenesis).
Normally, when the council issues too many emergency orders, the demolition crews develop "order fatigue" and slow down—but in this war economy, the crews working on civilian buildings (adipocytes, muscle) stop listening to the orders while the military fuel depot crews (immune cells) remain highly responsive. This selective deafness (cortisol resistance) ensures the military keeps getting fuel even as the orders stay at maximum volume.
Meanwhile, the city installs roadblocks (insulin resistance) at all civilian fuel stations to prevent non-military vehicles from taking any precious fuel. The army now consumes 10-20 times more fuel per soldier than peacetime because they're running advanced weapons systems (Warburg effect). Every day, more buildings come down. Eventually you have a city with a massive, fuel-hungry army, crumbling infrastructure, exhausted demolition crews still tearing down what's left, and no plan to ever declare peace. That's the energy supply strategy.
The energy supply strategy emerges through a coordinated cascade of metabolic and endocrine adaptations driven by chronic immune activation:
Initiating trigger:
Chronic inflammation → activated immune cells (macrophages, T cells, neutrophils) shift to Warburg effect metabolism → aerobic glycolysis consumes 10-20x more glucose per cell than oxidative phosphorylation → systemic glucose demand increases dramatically
Cortisol response:
Hypothalamus detects metabolic stress → CRH release → ACTH → sustained cortisol elevation (often 2-3x baseline) → cortisol binds glucocorticoid receptor in multiple tissues
Selective cortisol resistance development:
- Muscle and adipocytes: chronic cortisol exposure → glucocorticoid receptor downregulation → increased 11-β-hydroxysteroid dehydrogenase type 2 (converts active cortisol to inactive cortisone) → decreased cortisol sensitivity → requires higher cortisol levels for metabolic effects
- Immune cells: maintain glucocorticoid receptor sensitivity through SOCS3 suppression and maintained receptor expression → cortisol continues to drive glucose uptake and utilization → immune cells remain "cortisol-sensitive islands" in a cortisol-resistant body
Sustained gluconeogenesis:
High cortisol → hepatic activation of:
- PEPCK (phosphoenolpyruvate carboxykinase)
- G6Pase (glucose-6-phosphatase)
- FBPase (fructose-1,6-bisphosphatase)
→ Amino acids (75% from muscle) converted to glucose (200-300g daily) → alanine and glutamine are primary substrates → muscle protein catabolism increases 30-50% → progressive sarcopenia
Insulin resistance coordination:
TNF-α + IL-6 + sustained cortisol → serine phosphorylation of insulin receptor substrate-1 (IRS-1) → blocked insulin signaling in adipocytes and muscle → GLUT4 transporters remain internalized → peripheral tissues cannot take up glucose
Meanwhile: immune cells use GLUT1 transporter (insulin-independent) → continue glucose uptake regardless of insulin resistance → glucose preferentially directed to immune function
Treg dysfunction:
Metabolic stress → T regulatory cells shift from IL-10 production to interferon-gamma production → loss of anti-inflammatory control → further immune activation → increased glucose demand → vicious cycle amplification
graph TD
A[Chronic Inflammation] --> B[Immune Warburg Effect]
B --> C[Massive Glucose Demand]
C --> D[Hypothalamic Stress Response]
D --> E[Sustained Cortisol Elevation]
E --> F[Peripheral Cortisol Resistance]
E --> G[Immune Cortisol Sensitivity Maintained]
E --> H[Hepatic Gluconeogenesis]
H --> I[Muscle Protein Catabolism]
I --> J[Amino Acid Supply]
J --> H
E --> K[Insulin Resistance]
K --> L[Glucose Redirected to Immune Cells]
F --> M[Higher Cortisol Required]
M --> H
B --> N["Treg IFN-γ Production"]
N --> A
L --> B
Amplification mechanisms:
- FoxO1 transcription factor activation → increased autophagy and protein breakdown
- mTORC1 suppression → reduced protein synthesis
- Myostatin upregulation → muscle growth inhibition
- UCP1 suppression → reduced thermogenesis to conserve glucose
- Lactate from immune Warburg effect → hepatic conversion back to glucose (Cori cycle) → additional metabolic burden
The energy supply strategy is diagnostically and therapeutically central in cPNI because it explains the seemingly paradoxical metabolic phenotype of chronic disease patients who present with simultaneous hypercortisolaemia and cortisol resistance symptoms.
Relevant patient populations:
Metamodel connections:
This strategy represents the metabolic arm of the FILM meta-model's two-strategy framework. The body cannot sustain chronic inflammation without solving two problems: (1) continuous energy supply for immune cells (this strategy), and (2) tissue repair despite ongoing damage (growth and repair strategy). Both strategies require the body to "break the rules" of normal physiology—developing selective resistance to its own hormones.
The selfish immune system concept is perfectly embodied here: immune cells monopolize glucose through insulin-independent uptake while forcing peripheral tissues into starvation mode. This recapitulates evolutionary medicine principles where short-term immune survival trumps long-term metabolic health—a trade-off acceptable in acute infection but catastrophic when chronic.
Clinical thresholds and biomarkers:
- Morning cortisol >500 nmol/L (>18 µg/dL) with clinical signs of cortisol deficiency (fatigue, hypotension) suggests cortisol resistance
- Muscle mass loss >0.5 kg/month in non-cachectic patients indicates active protein catabolism
- HbA1c >5.7% with normal fasting glucose suggests insulin resistance compensating for immune glucose demand
- Neutrophil-lymphocyte ratio >3.0 indicates immune activation driving metabolic strategy
- CRP >3 mg/L with metabolic syndrome phenotype supports chronic inflammation-driven energy strategy
- HOMA-IR >2.5 documents insulin resistance component
- Low T regulatory cells (<4% of CD4+ T cells) with high interferon-gamma shows Treg dysfunction
Intervention implications:
Understanding this as a strategy (not a disease) fundamentally changes treatment approach:
-
Do not simply lower cortisol (adaptogens, phosphatidylserine, licorice withdrawal) without addressing root cause—this removes the compensatory mechanism maintaining glucose supply and can worsen fatigue
-
Provide alternative fuel sources:
-
Address cortisol resistance directly:
-
Reduce immune glucose demand:
-
Protein-sparing interventions:
- Leucine supplementation (3-4g TID) activates mTORC1 despite cortisol
- HMB (3g/day) reduces protein breakdown
- Creatine (5g/day) supports ATP production reducing protein catabolism for gluconeogenesis
- Resistance training creates anabolic signal overriding catabolic drive
-
Insulin sensitivity restoration:
The goal is not metabolic "normalization" while inflammation persists—that's impossible—but rather reducing the metabolic cost of the strategy while working toward inflammation resolution.
- Activated immune cells using Warburg effect consume 10-20x more glucose than the same cells at rest
- Muscle tissue provides 75% of amino acids for gluconeogenesis during sustained catabolism—primarily alanine and glutamine
- Cortisol resistance develops selectively: adipocytes and muscle become resistant while immune cells maintain sensitivity through differential 11-β-hydroxysteroid dehydrogenase and SOCS3 expression
- Chronic inflammation increases whole-body protein turnover by 30-50% above baseline
- Hepatic gluconeogenesis can produce 200-300g glucose daily from amino acids alone when sustained by high cortisol
- T regulatory cells shift from producing anti-inflammatory IL-10 to pro-inflammatory interferon-gamma under conditions of energy supply stress—this represents a failure of immune regulation that amplifies the vicious cycle
- The human liver contains enough glycogen for only 12-18 hours of fasting—beyond this, all glucose must come from gluconeogenesis or dietary intake
- Insulin resistance in muscle and fat develops within 3-5 days of sustained inflammation through TNF-α-mediated serine phosphorylation of IRS-1
- Immune cells preferentially use GLUT1 transporter (insulin-independent) rather than GLUT4 transporters (insulin-dependent), allowing them to bypass insulin resistance
- The energy supply strategy overlaps extensively with metabolic syndrome phenotype: central obesity (cortisol), hypertension (insulin resistance, cortisol), dyslipidemia (insulin resistance), hyperglycaemia (gluconeogenesis)
- Cancer cachexia represents an extreme version where tumor-derived cytokines (IL-6, TNF-α, interferon-gamma) drive the energy supply strategy to fatal endpoint with 30% body weight loss
- Morning cortisol levels may be normal or even low-normal in late-stage cortisol resistance as adrenal output can no longer maintain the elevated levels required
- FILM meta-model — energy supply strategy forms the metabolic pillar alongside growth and repair strategy in FILM's two-strategy framework for chronic disease
- cortisol resistance — selective peripheral cortisol resistance is the core enabling mechanism that allows sustained high cortisol to drive gluconeogenesis without suppressing immune function
- gluconeogenesis — sustained hepatic conversion of amino acids to glucose is the primary metabolic output of the energy supply strategy
- selfish immune system — immune cells monopolize glucose supply through insulin-independent uptake and Warburg metabolism, exemplifying selfish system behavior
- chronic inflammation — creates the initial metabolic demand that necessitates the energy supply strategy and maintains it through continuous immune activation
- muscle wasting — progressive sarcopenia from protein catabolism is the most visible clinical manifestation of sustained energy supply strategy
- insulin resistance — develops coordinately with cortisol resistance to preserve glucose for immune cells by blocking peripheral tissue uptake
- cortisol — remains elevated despite peripheral resistance to maintain gluconeogenesis; immune cells retain cortisol sensitivity while other tissues become resistant
- metabolic syndrome — the constellation of insulin resistance, central obesity, hypertension, and dyslipidemia emerges as manifestation of energy supply strategy
- Warburg effect — immune cell shift to aerobic glycolysis creates the 10-20x increase in glucose demand that drives the entire energy supply strategy
- protein catabolism — muscle protein breakdown accelerates 30-50% to provide amino acid substrates for hepatic gluconeogenesis
- T regulatory cells — shift from IL-10 to IFN-γ production under metabolic stress, losing regulatory function and amplifying inflammation
- interferon-gamma — replaces IL-10 as primary Treg cytokine during energy crisis, driving further inflammation rather than resolution
- IL-10 — anti-inflammatory cytokine production decreases in Tregs as cells prioritize energy-intensive inflammatory functions
- chronic fatigue — metabolic depletion from sustained gluconeogenesis and muscle catabolism manifests as profound fatigue despite "high" cortisol
- sarcopenia — age-related muscle loss accelerates dramatically when energy supply strategy operates chronically
- type 2 diabetes — progressive insulin resistance from energy supply strategy can overwhelm beta-cell compensation leading to diabetes
- growth and repair strategy — the complementary strategy in FILM model that maintains tissue repair through growth hormone resistance while energy supply strategy maintains glucose availability
- ketogenesis — therapeutic intervention that reduces glucose dependency by providing alternative fuel, lowering burden on gluconeogenesis
- beta-oxidation — shifting energy metabolism toward fat oxidation reduces immune glucose demand and gluconeogenesis requirement
- 11-β-hydroxysteroid dehydrogenase — enzyme that converts active cortisol to inactive cortisone; upregulated in peripheral tissues during cortisol resistance development
- glucocorticoid receptor — downregulated in muscle and adipose during chronic cortisol exposure but maintained in immune cells, creating selective resistance pattern
- GLUT1 transporter — insulin-independent glucose transporter used by immune cells allowing glucose uptake despite systemic insulin resistance
- GLUT4 transporters — insulin-dependent glucose transporters in muscle and adipose that remain internalized during insulin resistance, blocking peripheral glucose uptake
- FoxO1 — transcription factor activated by cortisol and insulin resistance that drives protein breakdown and autophagy
- mTORC1 — anabolic signaling pathway suppressed by cortisol and inflammatory cytokines, reducing protein synthesis
- TNF-α — pro-inflammatory cytokine that induces insulin resistance through IRS-1 serine phosphorylation
- IL-6 — dual-role cytokine that drives both insulin resistance and hepatic acute phase response supporting energy supply strategy
- SOCS3 — suppressor of cytokine signaling that modulates glucocorticoid receptor sensitivity; suppressed in immune cells maintaining cortisol sensitivity
- HbA1c — biomarker of chronic hyperglycemia resulting from sustained gluconeogenesis and insulin resistance
- neutrophil-lymphocyte ratio — biomarker of immune activation indicating active energy supply strategy when elevated >3.0
- C-reactive protein — acute phase protein marker of inflammation driving metabolic reconfiguration
- Lactate — byproduct of immune Warburg metabolism that returns to liver for reconversion to glucose via Cori cycle, adding metabolic burden